Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Han X, Tang X, Zhu H, Zhu D, Zhang X, Meng X, Hua Y, Wang Z, Zhang Y, Huang W, Wang L, Yuan S, Zhang P, Gong H, Sun Y, Zhang Y, Liu Z, Dong X, Gai F, Huang Z, Zhu C, Guo J, Wang Z.
Han X, et al. Among authors: zhang p, zhang x, zhang y.
J Immunother Cancer. 2022 Dec;10(12):e004952. doi: 10.1136/jitc-2022-004952.
J Immunother Cancer. 2022.
PMID: 36600554
Free PMC article.
Clinical Trial.